26
Participants
Start Date
November 30, 2014
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Lorazepam
"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
Aichi Children's Health and Medical Center, Obu-shi
National Hospital Organization Fukuoka-Higashi Medical Center, Koga
Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo
Nakamura Memorial Hospital, Sapporo
National Hospital Organization Hokkaido Medical Center, Sapporo
Hyogo Prefectural Kobe Children's Hospital, Kobe
Tohoku University Hospital, Sendai
National Hospital Organization Nagasaki Medical Center, Ohmura
National Nishi-Niigata Central Hospital / Pediatrics, Niigata
Okayama University Hospital / Child Neurology, Okayama
Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi
Osaka City General Hospital Pediatric Neurology, Miyakojima-ku
NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
National Center of Neurology and Psychiatry, Kodaira
Yamanashi Prefectural Central Hospital, Kofu
Fukuoka Children's Hospital, Fukuoka
Fukuoka Sanno Hospital, Fukuoka
Fukuoka University Hospital, Fukuoka
Gifu Prefectural General Medical Center, Gifu
Saitama Children's Medical Center, Saitama
Lead Sponsor
Pfizer
INDUSTRY